Jeffrey Montgomery
Concepts (434)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 52 | 2025 | 166 | 9.200 |
Why?
| | Cystectomy | 32 | 2025 | 52 | 6.120 |
Why?
| | Prostatic Neoplasms | 42 | 2024 | 398 | 4.700 |
Why?
| | Kidney Neoplasms | 22 | 2018 | 181 | 2.590 |
Why?
| | Carcinoma, Transitional Cell | 13 | 2023 | 54 | 2.520 |
Why?
| | Prostatectomy | 22 | 2023 | 84 | 2.210 |
Why?
| | Nephrectomy | 19 | 2016 | 81 | 1.870 |
Why?
| | Lymph Node Excision | 7 | 2024 | 133 | 1.720 |
Why?
| | Urinary Diversion | 6 | 2021 | 43 | 1.530 |
Why?
| | Laparoscopy | 13 | 2014 | 180 | 1.440 |
Why?
| | Quality of Life | 13 | 2025 | 893 | 1.400 |
Why?
| | Prostate | 13 | 2024 | 116 | 1.340 |
Why?
| | Aged | 80 | 2025 | 10242 | 1.240 |
Why?
| | Male | 119 | 2025 | 26874 | 1.160 |
Why?
| | Middle Aged | 86 | 2025 | 13133 | 1.100 |
Why?
| | Humans | 148 | 2025 | 52441 | 1.100 |
Why?
| | Neoadjuvant Therapy | 12 | 2024 | 124 | 1.070 |
Why?
| | Neoplasm Staging | 25 | 2024 | 768 | 0.960 |
Why?
| | BCG Vaccine | 7 | 2024 | 16 | 0.920 |
Why?
| | Robotics | 8 | 2015 | 43 | 0.910 |
Why?
| | Postoperative Complications | 15 | 2021 | 1065 | 0.870 |
Why?
| | Carcinoma, Renal Cell | 10 | 2016 | 112 | 0.850 |
Why?
| | Retrospective Studies | 51 | 2024 | 6694 | 0.840 |
Why?
| | Neoplasm Recurrence, Local | 15 | 2025 | 639 | 0.840 |
Why?
| | Penile Neoplasms | 3 | 2024 | 45 | 0.830 |
Why?
| | Exercise Therapy | 1 | 2023 | 101 | 0.770 |
Why?
| | Ureter | 3 | 2016 | 35 | 0.770 |
Why?
| | Exercise | 2 | 2023 | 559 | 0.750 |
Why?
| | Hernia | 2 | 2020 | 6 | 0.720 |
Why?
| | Treatment Outcome | 31 | 2025 | 5508 | 0.680 |
Why?
| | Intestine, Small | 2 | 2020 | 112 | 0.670 |
Why?
| | Physical Fitness | 1 | 2020 | 56 | 0.650 |
Why?
| | Herniorrhaphy | 1 | 2020 | 32 | 0.650 |
Why?
| | Aged, 80 and over | 27 | 2025 | 3449 | 0.650 |
Why?
| | Intestinal Obstruction | 1 | 2020 | 36 | 0.640 |
Why?
| | Neoplasm Invasiveness | 15 | 2025 | 278 | 0.620 |
Why?
| | Patient Readmission | 6 | 2021 | 249 | 0.620 |
Why?
| | Image-Guided Biopsy | 6 | 2024 | 35 | 0.620 |
Why?
| | Watchful Waiting | 7 | 2019 | 29 | 0.600 |
Why?
| | Biopsy | 17 | 2023 | 594 | 0.570 |
Why?
| | Ureteral Neoplasms | 2 | 2018 | 11 | 0.570 |
Why?
| | Female | 59 | 2025 | 28277 | 0.540 |
Why?
| | Organ Sparing Treatments | 5 | 2025 | 58 | 0.530 |
Why?
| | Testicular Neoplasms | 4 | 2024 | 46 | 0.520 |
Why?
| | Magnetic Resonance Imaging | 10 | 2023 | 1507 | 0.520 |
Why?
| | Urinary Bladder | 7 | 2018 | 101 | 0.510 |
Why?
| | Convalescence | 1 | 2016 | 6 | 0.500 |
Why?
| | Prospective Studies | 18 | 2025 | 2433 | 0.500 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2024 | 331 | 0.500 |
Why?
| | Neoplasm Grading | 14 | 2025 | 127 | 0.480 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2024 | 20 | 0.470 |
Why?
| | Urothelium | 4 | 2018 | 19 | 0.460 |
Why?
| | Carcinoma in Situ | 4 | 2024 | 72 | 0.460 |
Why?
| | Chemotherapy, Adjuvant | 8 | 2024 | 122 | 0.450 |
Why?
| | Ileum | 1 | 2014 | 87 | 0.430 |
Why?
| | Urologic Neoplasms | 3 | 2019 | 12 | 0.430 |
Why?
| | Choline | 3 | 2019 | 64 | 0.430 |
Why?
| | Medical Oncology | 4 | 2021 | 97 | 0.420 |
Why?
| | Quality Indicators, Health Care | 1 | 2013 | 91 | 0.380 |
Why?
| | Needles | 3 | 2021 | 26 | 0.370 |
Why?
| | Administration, Intravesical | 7 | 2024 | 16 | 0.370 |
Why?
| | Urologic Surgical Procedures | 3 | 2016 | 30 | 0.370 |
Why?
| | Disease Progression | 8 | 2024 | 870 | 0.360 |
Why?
| | Lymphatic Metastasis | 4 | 2024 | 210 | 0.360 |
Why?
| | Antineoplastic Agents | 3 | 2021 | 1216 | 0.360 |
Why?
| | Biopsy, Needle | 5 | 2021 | 181 | 0.350 |
Why?
| | Prostate-Specific Antigen | 8 | 2021 | 41 | 0.350 |
Why?
| | Survival Rate | 9 | 2021 | 944 | 0.350 |
Why?
| | Testicular Diseases | 1 | 2011 | 9 | 0.340 |
Why?
| | Risk Assessment | 10 | 2019 | 1349 | 0.340 |
Why?
| | Urogenital Neoplasms | 1 | 2010 | 9 | 0.330 |
Why?
| | Muscle Neoplasms | 1 | 2010 | 16 | 0.330 |
Why?
| | Magnetic Resonance Imaging, Interventional | 4 | 2024 | 5 | 0.330 |
Why?
| | Registries | 4 | 2023 | 638 | 0.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1020 | 0.310 |
Why?
| | Fluorine Radioisotopes | 2 | 2019 | 25 | 0.310 |
Why?
| | Retroperitoneal Space | 5 | 2016 | 25 | 0.310 |
Why?
| | Recovery of Function | 2 | 2023 | 201 | 0.310 |
Why?
| | Adult | 27 | 2024 | 14205 | 0.300 |
Why?
| | Psoas Muscles | 2 | 2021 | 2 | 0.300 |
Why?
| | Self Report | 1 | 2010 | 221 | 0.300 |
Why?
| | Telomerase | 2 | 2019 | 26 | 0.290 |
Why?
| | Patient Selection | 5 | 2019 | 269 | 0.290 |
Why?
| | Urinary Incontinence | 3 | 2023 | 40 | 0.280 |
Why?
| | Seat Belts | 2 | 2017 | 17 | 0.270 |
Why?
| | Child Restraint Systems | 2 | 2017 | 18 | 0.270 |
Why?
| | Urinary Catheterization | 1 | 2007 | 24 | 0.270 |
Why?
| | Positron-Emission Tomography | 2 | 2019 | 297 | 0.270 |
Why?
| | Urethral Stricture | 1 | 2007 | 23 | 0.270 |
Why?
| | Time Factors | 13 | 2020 | 2987 | 0.260 |
Why?
| | Primary Health Care | 1 | 2011 | 387 | 0.260 |
Why?
| | Rectum | 2 | 2024 | 55 | 0.260 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 1140 | 0.250 |
Why?
| | Cohort Studies | 8 | 2021 | 1576 | 0.250 |
Why?
| | Guideline Adherence | 3 | 2017 | 142 | 0.250 |
Why?
| | Length of Stay | 6 | 2020 | 673 | 0.250 |
Why?
| | Health Status | 2 | 2015 | 300 | 0.240 |
Why?
| | Patient Discharge | 3 | 2017 | 320 | 0.240 |
Why?
| | Pain Measurement | 2 | 2017 | 263 | 0.240 |
Why?
| | Patient Participation | 2 | 2016 | 65 | 0.230 |
Why?
| | Tumor Burden | 5 | 2016 | 132 | 0.230 |
Why?
| | Kidney | 4 | 2014 | 716 | 0.230 |
Why?
| | Bandages | 1 | 2005 | 27 | 0.230 |
Why?
| | Carcinoma | 2 | 2018 | 135 | 0.230 |
Why?
| | Adenoviridae | 2 | 2024 | 46 | 0.220 |
Why?
| | Surgical Wound Infection | 1 | 2005 | 118 | 0.220 |
Why?
| | Neurilemmoma | 1 | 2004 | 24 | 0.220 |
Why?
| | Age Factors | 7 | 2021 | 1120 | 0.220 |
Why?
| | Multivariate Analysis | 8 | 2016 | 601 | 0.220 |
Why?
| | Adenocarcinoma | 3 | 2016 | 403 | 0.220 |
Why?
| | Immunohistochemistry | 5 | 2024 | 977 | 0.220 |
Why?
| | Quality Improvement | 3 | 2016 | 226 | 0.220 |
Why?
| | Venous Thrombosis | 1 | 2005 | 89 | 0.210 |
Why?
| | Follow-Up Studies | 9 | 2024 | 2294 | 0.210 |
Why?
| | Perineum | 1 | 2024 | 26 | 0.210 |
Why?
| | Decision Making | 2 | 2016 | 273 | 0.210 |
Why?
| | Antibiotic Prophylaxis | 1 | 2024 | 63 | 0.200 |
Why?
| | Clinical Competence | 3 | 2016 | 405 | 0.200 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 498 | 0.200 |
Why?
| | Urethra | 3 | 2014 | 97 | 0.190 |
Why?
| | Erectile Dysfunction | 3 | 2023 | 94 | 0.190 |
Why?
| | United States | 12 | 2020 | 5215 | 0.190 |
Why?
| | DNA, Neoplasm | 2 | 2018 | 146 | 0.180 |
Why?
| | Logistic Models | 7 | 2021 | 930 | 0.180 |
Why?
| | Feasibility Studies | 2 | 2020 | 404 | 0.180 |
Why?
| | Vital Statistics | 1 | 2021 | 3 | 0.180 |
Why?
| | Mandatory Reporting | 1 | 2021 | 12 | 0.170 |
Why?
| | Death Certificates | 1 | 2021 | 15 | 0.170 |
Why?
| | DNA Mutational Analysis | 3 | 2018 | 179 | 0.170 |
Why?
| | Birth Certificates | 1 | 2021 | 24 | 0.170 |
Why?
| | Cell Transdifferentiation | 1 | 2021 | 8 | 0.170 |
Why?
| | Cost-Benefit Analysis | 2 | 2019 | 271 | 0.170 |
Why?
| | Neuroendocrine Cells | 1 | 2021 | 9 | 0.170 |
Why?
| | Reproducibility of Results | 7 | 2018 | 1223 | 0.170 |
Why?
| | Urethral Diseases | 2 | 2013 | 7 | 0.170 |
Why?
| | Prognosis | 8 | 2021 | 2100 | 0.170 |
Why?
| | Radiosurgery | 1 | 2022 | 130 | 0.170 |
Why?
| | Radiography, Abdominal | 1 | 2020 | 24 | 0.170 |
Why?
| | Mutation | 5 | 2019 | 1331 | 0.170 |
Why?
| | Reimbursement, Incentive | 1 | 2020 | 12 | 0.160 |
Why?
| | Genetic Vectors | 1 | 2020 | 128 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 625 | 0.160 |
Why?
| | Ablation Techniques | 1 | 2019 | 19 | 0.160 |
Why?
| | Genetic Therapy | 1 | 2020 | 127 | 0.160 |
Why?
| | Abdominal Pain | 1 | 2020 | 83 | 0.160 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 1028 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 80 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 5 | 2024 | 525 | 0.150 |
Why?
| | Adjuvants, Immunologic | 3 | 2024 | 51 | 0.150 |
Why?
| | Urinary Tract | 1 | 2018 | 23 | 0.150 |
Why?
| | Lymphocytes | 1 | 2019 | 146 | 0.150 |
Why?
| | Forecasting | 1 | 2019 | 151 | 0.150 |
Why?
| | Predictive Value of Tests | 6 | 2018 | 938 | 0.150 |
Why?
| | Obesity | 2 | 2006 | 1176 | 0.150 |
Why?
| | Neutrophils | 1 | 2019 | 148 | 0.140 |
Why?
| | Patient-Centered Care | 1 | 2020 | 141 | 0.140 |
Why?
| | Genetic Heterogeneity | 1 | 2018 | 20 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 45 | 0.140 |
Why?
| | Internship and Residency | 2 | 2021 | 438 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 46 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 336 | 0.140 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2018 | 17 | 0.140 |
Why?
| | Orchiectomy | 1 | 2018 | 38 | 0.140 |
Why?
| | Transurethral Resection of Prostate | 1 | 2018 | 10 | 0.140 |
Why?
| | Pain, Postoperative | 2 | 2016 | 169 | 0.140 |
Why?
| | Body Size | 1 | 2017 | 32 | 0.140 |
Why?
| | Quality Assurance, Health Care | 1 | 2018 | 147 | 0.140 |
Why?
| | Physician-Patient Relations | 2 | 2016 | 142 | 0.130 |
Why?
| | Inguinal Canal | 1 | 2017 | 11 | 0.130 |
Why?
| | Urodynamics | 2 | 2014 | 24 | 0.130 |
Why?
| | Sarcosine | 1 | 2017 | 3 | 0.130 |
Why?
| | Amino Acid Transport Systems | 1 | 2017 | 5 | 0.130 |
Why?
| | Anticoagulants | 1 | 2020 | 276 | 0.130 |
Why?
| | Databases, Factual | 2 | 2021 | 721 | 0.130 |
Why?
| | Body Height | 1 | 2017 | 65 | 0.130 |
Why?
| | Electronic Health Records | 1 | 2020 | 274 | 0.130 |
Why?
| | Safety | 1 | 2017 | 78 | 0.130 |
Why?
| | Carbon Radioisotopes | 1 | 2017 | 54 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2017 | 111 | 0.130 |
Why?
| | Disease-Free Survival | 5 | 2016 | 461 | 0.130 |
Why?
| | Transcriptome | 2 | 2018 | 357 | 0.130 |
Why?
| | Replantation | 1 | 2016 | 11 | 0.130 |
Why?
| | Scrotum | 2 | 2015 | 31 | 0.130 |
Why?
| | Nomograms | 1 | 2016 | 7 | 0.130 |
Why?
| | Protons | 1 | 2017 | 74 | 0.130 |
Why?
| | Laparotomy | 1 | 2016 | 36 | 0.120 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2016 | 6 | 0.120 |
Why?
| | Physicians | 2 | 2016 | 237 | 0.120 |
Why?
| | Research Report | 1 | 2016 | 19 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 5 | 2017 | 485 | 0.120 |
Why?
| | Urinary Retention | 2 | 2007 | 7 | 0.120 |
Why?
| | Patient Preference | 1 | 2016 | 43 | 0.120 |
Why?
| | Ureteral Obstruction | 1 | 2016 | 62 | 0.120 |
Why?
| | Checklist | 1 | 2016 | 39 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2016 | 77 | 0.120 |
Why?
| | Preoperative Period | 3 | 2021 | 47 | 0.120 |
Why?
| | Sensitivity and Specificity | 5 | 2018 | 871 | 0.120 |
Why?
| | Genital Neoplasms, Male | 1 | 2015 | 2 | 0.120 |
Why?
| | Paget Disease, Extramammary | 1 | 2015 | 5 | 0.120 |
Why?
| | Social Networking | 1 | 2015 | 17 | 0.120 |
Why?
| | Body Weight | 1 | 2017 | 524 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2017 | 253 | 0.110 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 198 | 0.110 |
Why?
| | Feedback | 1 | 2015 | 52 | 0.110 |
Why?
| | Treatment Failure | 2 | 2017 | 117 | 0.110 |
Why?
| | Video Recording | 1 | 2015 | 79 | 0.110 |
Why?
| | Informed Consent | 1 | 2015 | 92 | 0.110 |
Why?
| | Peer Group | 1 | 2015 | 61 | 0.110 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2015 | 75 | 0.110 |
Why?
| | Papilloma, Inverted | 1 | 2014 | 1 | 0.110 |
Why?
| | Equipment Design | 3 | 2021 | 287 | 0.110 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 67 | 0.110 |
Why?
| | Computer Simulation | 1 | 2015 | 285 | 0.110 |
Why?
| | Blood Loss, Surgical | 5 | 2016 | 70 | 0.110 |
Why?
| | Matched-Pair Analysis | 1 | 2013 | 11 | 0.110 |
Why?
| | Urinary Incontinence, Stress | 1 | 2014 | 32 | 0.100 |
Why?
| | Adenoma | 1 | 2015 | 114 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2016 | 230 | 0.100 |
Why?
| | Diffusion of Innovation | 1 | 2013 | 47 | 0.100 |
Why?
| | Carcinoma, Papillary | 1 | 2014 | 49 | 0.100 |
Why?
| | Body Mass Index | 3 | 2020 | 701 | 0.100 |
Why?
| | General Surgery | 1 | 2015 | 106 | 0.100 |
Why?
| | Technology Transfer | 1 | 2013 | 2 | 0.100 |
Why?
| | Mitomycin | 1 | 2013 | 20 | 0.100 |
Why?
| | Longitudinal Studies | 2 | 2018 | 756 | 0.100 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 65 | 0.100 |
Why?
| | Accreditation | 1 | 2013 | 62 | 0.100 |
Why?
| | Peripheral Nerves | 1 | 2013 | 47 | 0.100 |
Why?
| | Education, Medical, Continuing | 1 | 2013 | 76 | 0.100 |
Why?
| | Referral and Consultation | 2 | 2012 | 288 | 0.090 |
Why?
| | Operating Rooms | 1 | 2012 | 27 | 0.090 |
Why?
| | Community Health Centers | 1 | 2012 | 30 | 0.090 |
Why?
| | Pathology, Clinical | 1 | 2012 | 25 | 0.090 |
Why?
| | Receptors, Androgen | 2 | 2002 | 48 | 0.090 |
Why?
| | Algorithms | 1 | 2015 | 673 | 0.090 |
Why?
| | Combined Modality Therapy | 3 | 2021 | 641 | 0.090 |
Why?
| | Neoplasms | 1 | 2021 | 1314 | 0.090 |
Why?
| | Risk Factors | 5 | 2017 | 3971 | 0.080 |
Why?
| | Perioperative Care | 1 | 2011 | 43 | 0.080 |
Why?
| | Seminal Vesicles | 2 | 2022 | 13 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2015 | 496 | 0.080 |
Why?
| | Phantoms, Imaging | 2 | 2020 | 118 | 0.080 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 112 | 0.080 |
Why?
| | Medicare | 3 | 2020 | 281 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1045 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 446 | 0.070 |
Why?
| | Markov Chains | 2 | 2019 | 29 | 0.070 |
Why?
| | Immunotherapy | 1 | 2010 | 251 | 0.070 |
Why?
| | Carboplatin | 2 | 2022 | 55 | 0.070 |
Why?
| | SEER Program | 3 | 2014 | 105 | 0.070 |
Why?
| | Postoperative Care | 2 | 2020 | 104 | 0.070 |
Why?
| | Healthcare Disparities | 1 | 2011 | 291 | 0.070 |
Why?
| | Ureteroscopy | 1 | 2007 | 10 | 0.070 |
Why?
| | Pandemics | 2 | 2023 | 580 | 0.070 |
Why?
| | Automobiles | 2 | 2017 | 13 | 0.070 |
Why?
| | Sarcopenia | 2 | 2021 | 99 | 0.070 |
Why?
| | Chi-Square Distribution | 3 | 2013 | 292 | 0.070 |
Why?
| | Diverticulum | 1 | 2007 | 21 | 0.070 |
Why?
| | Incidence | 2 | 2021 | 1096 | 0.070 |
Why?
| | Peritoneum | 1 | 2007 | 16 | 0.070 |
Why?
| | Cisplatin | 2 | 2022 | 282 | 0.070 |
Why?
| | Delphi Technique | 2 | 2018 | 66 | 0.070 |
Why?
| | Aftercare | 2 | 2018 | 67 | 0.070 |
Why?
| | Gene Amplification | 2 | 2018 | 59 | 0.070 |
Why?
| | Societies, Medical | 2 | 2018 | 200 | 0.060 |
Why?
| | Adrenalectomy | 1 | 2006 | 33 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2019 | 465 | 0.060 |
Why?
| | Postoperative Hemorrhage | 1 | 2006 | 54 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2014 | 1202 | 0.060 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2005 | 13 | 0.060 |
Why?
| | Sex Factors | 2 | 2020 | 735 | 0.060 |
Why?
| | Hand | 1 | 2005 | 51 | 0.060 |
Why?
| | Tissue Adhesives | 1 | 2005 | 15 | 0.060 |
Why?
| | Genomics | 2 | 2018 | 266 | 0.060 |
Why?
| | Intestines | 1 | 2006 | 159 | 0.060 |
Why?
| | Suture Techniques | 1 | 2005 | 59 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2005 | 109 | 0.060 |
Why?
| | Diabetes Complications | 1 | 2005 | 124 | 0.060 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2024 | 13 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2016 | 126 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2024 | 51 | 0.050 |
Why?
| | Superior Mesenteric Artery Syndrome | 1 | 2004 | 3 | 0.050 |
Why?
| | Mediastinal Neoplasms | 1 | 2024 | 19 | 0.050 |
Why?
| | Communication | 2 | 2016 | 255 | 0.050 |
Why?
| | Deoxycytidine | 2 | 2014 | 24 | 0.050 |
Why?
| | Hernia, Inguinal | 1 | 2004 | 20 | 0.050 |
Why?
| | Intraoperative Complications | 1 | 2005 | 113 | 0.050 |
Why?
| | Phenotype | 2 | 2018 | 792 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2015 | 178 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2018 | 1429 | 0.050 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 75 | 0.050 |
Why?
| | Child | 3 | 2024 | 7194 | 0.050 |
Why?
| | Quality of Health Care | 2 | 2015 | 186 | 0.050 |
Why?
| | Ischemia | 1 | 2004 | 150 | 0.050 |
Why?
| | Papillomavirus Infections | 2 | 2015 | 170 | 0.050 |
Why?
| | Perioperative Period | 2 | 2013 | 21 | 0.050 |
Why?
| | Trinucleotide Repeats | 1 | 2002 | 4 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2005 | 243 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2024 | 295 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 108 | 0.050 |
Why?
| | Odds Ratio | 2 | 2014 | 563 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2002 | 65 | 0.050 |
Why?
| | Smoking | 1 | 2005 | 514 | 0.050 |
Why?
| | Accidents, Traffic | 2 | 2017 | 91 | 0.050 |
Why?
| | Gallium Isotopes | 1 | 2021 | 2 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2021 | 9 | 0.040 |
Why?
| | Edetic Acid | 1 | 2021 | 13 | 0.040 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2013 | 184 | 0.040 |
Why?
| | Androgen Antagonists | 1 | 2021 | 12 | 0.040 |
Why?
| | Geography | 1 | 2021 | 65 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 506 | 0.040 |
Why?
| | Quarantine | 1 | 2021 | 11 | 0.040 |
Why?
| | Public Health | 1 | 2023 | 224 | 0.040 |
Why?
| | Internationality | 1 | 2021 | 46 | 0.040 |
Why?
| | Neoplasm Metastasis | 2 | 2017 | 235 | 0.040 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 11 | 0.040 |
Why?
| | Motion | 1 | 2020 | 19 | 0.040 |
Why?
| | Enoxaparin | 1 | 2020 | 31 | 0.040 |
Why?
| | Finite Element Analysis | 1 | 2020 | 11 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 123 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 81 | 0.040 |
Why?
| | Pelvis | 1 | 2020 | 65 | 0.040 |
Why?
| | Abdomen | 1 | 2020 | 71 | 0.040 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2019 | 11 | 0.040 |
Why?
| | Young Adult | 2 | 2024 | 4346 | 0.040 |
Why?
| | Heparin | 1 | 2020 | 88 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 169 | 0.040 |
Why?
| | Social Behavior | 1 | 2019 | 74 | 0.040 |
Why?
| | Urine | 1 | 2018 | 26 | 0.040 |
Why?
| | Adolescent | 2 | 2024 | 6713 | 0.040 |
Why?
| | Cytodiagnosis | 1 | 2018 | 42 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2018 | 69 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2018 | 118 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 234 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 116 | 0.030 |
Why?
| | Genome, Human | 1 | 2018 | 121 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2018 | 67 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 96 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 286 | 0.030 |
Why?
| | Hospitalization | 2 | 2017 | 731 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 51 | 0.030 |
Why?
| | Health Services Accessibility | 2 | 2012 | 444 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 1365 | 0.030 |
Why?
| | Nephrons | 1 | 2016 | 6 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2017 | 175 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 195 | 0.030 |
Why?
| | Hospital Communication Systems | 1 | 2016 | 5 | 0.030 |
Why?
| | Coitus | 1 | 2016 | 18 | 0.030 |
Why?
| | Failure to Thrive | 1 | 2016 | 19 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2016 | 69 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 137 | 0.030 |
Why?
| | Radiometry | 1 | 2017 | 125 | 0.030 |
Why?
| | Creatinine | 1 | 2016 | 156 | 0.030 |
Why?
| | Molecular Imaging | 1 | 2016 | 28 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 185 | 0.030 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2015 | 10 | 0.030 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2015 | 12 | 0.030 |
Why?
| | Operative Time | 1 | 2016 | 76 | 0.030 |
Why?
| | Genes, erbB-1 | 1 | 2015 | 9 | 0.030 |
Why?
| | Tape Recording | 1 | 2015 | 7 | 0.030 |
Why?
| | Fever | 1 | 2016 | 112 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2011 | 609 | 0.030 |
Why?
| | Learning Curve | 1 | 2015 | 20 | 0.030 |
Why?
| | Groin | 1 | 2015 | 16 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 45 | 0.030 |
Why?
| | Oncology Service, Hospital | 1 | 2014 | 14 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2015 | 49 | 0.030 |
Why?
| | Vinblastine | 1 | 2014 | 22 | 0.030 |
Why?
| | Europe | 1 | 2014 | 90 | 0.030 |
Why?
| | North America | 1 | 2014 | 75 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 400 | 0.030 |
Why?
| | Incontinence Pads | 1 | 2014 | 2 | 0.030 |
Why?
| | Kidney Failure, Chronic | 1 | 2016 | 205 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 2014 | 69 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 79 | 0.030 |
Why?
| | Personal Satisfaction | 1 | 2014 | 74 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 853 | 0.030 |
Why?
| | Gene Dosage | 1 | 2014 | 73 | 0.030 |
Why?
| | Ultrasonography | 1 | 2016 | 416 | 0.030 |
Why?
| | Methotrexate | 1 | 2014 | 76 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 291 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2014 | 102 | 0.030 |
Why?
| | Anxiety | 1 | 2016 | 305 | 0.030 |
Why?
| | Survivors | 1 | 2014 | 121 | 0.030 |
Why?
| | Dysuria | 1 | 2013 | 1 | 0.030 |
Why?
| | Anesthesiology | 1 | 2014 | 37 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 236 | 0.030 |
Why?
| | Prevalence | 1 | 2016 | 1016 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 220 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2013 | 30 | 0.030 |
Why?
| | Valsalva Maneuver | 1 | 2013 | 10 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1099 | 0.030 |
Why?
| | Stents | 1 | 2016 | 368 | 0.020 |
Why?
| | Diagnostic Tests, Routine | 1 | 2013 | 31 | 0.020 |
Why?
| | Health Services Research | 1 | 2013 | 153 | 0.020 |
Why?
| | Paclitaxel | 1 | 2013 | 91 | 0.020 |
Why?
| | Doxorubicin | 1 | 2014 | 246 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2013 | 158 | 0.020 |
Why?
| | Neutropenia | 1 | 2013 | 113 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 83 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2013 | 93 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 656 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 358 | 0.020 |
Why?
| | Angiomyolipoma | 1 | 2012 | 9 | 0.020 |
Why?
| | Unnecessary Procedures | 1 | 2012 | 20 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2013 | 169 | 0.020 |
Why?
| | Tertiary Care Centers | 1 | 2012 | 83 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 725 | 0.020 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2012 | 44 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2012 | 104 | 0.020 |
Why?
| | Patient Positioning | 1 | 2011 | 31 | 0.020 |
Why?
| | Urination Disorders | 1 | 2010 | 23 | 0.020 |
Why?
| | Disease Management | 1 | 2012 | 185 | 0.020 |
Why?
| | Organ Size | 1 | 2010 | 226 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 637 | 0.020 |
Why?
| | Health Status Disparities | 1 | 2011 | 218 | 0.020 |
Why?
| | Intraoperative Period | 1 | 2007 | 46 | 0.020 |
Why?
| | Erythrocyte Transfusion | 1 | 2006 | 52 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2006 | 94 | 0.020 |
Why?
| | Decision Trees | 1 | 2005 | 23 | 0.010 |
Why?
| | Portal System | 1 | 2005 | 17 | 0.010 |
Why?
| | Collateral Circulation | 1 | 2005 | 38 | 0.010 |
Why?
| | Hypertension, Portal | 1 | 2005 | 23 | 0.010 |
Why?
| | Reoperation | 1 | 2006 | 463 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2005 | 126 | 0.010 |
Why?
| | Short Bowel Syndrome | 1 | 2004 | 17 | 0.010 |
Why?
| | Necrosis | 1 | 2004 | 169 | 0.010 |
Why?
| | Liver Transplantation | 1 | 2005 | 171 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2002 | 184 | 0.010 |
Why?
| | Genetic Markers | 1 | 2002 | 108 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 199 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 632 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2002 | 458 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 778 | 0.010 |
Why?
|
|
Montgomery's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|